Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Chronic hepatitis B prognostic markers other than pre-treatment viral load predicted composite treatment outcome
Authors: Aung, Myo Nyein
Wattana Leowattana
วัฒนา เลี้ยววัฒนา
Win, Khine Nwe
Noppadon Tangpukdee
นพดล ตั้งภักดี
Sant Muangnoicharoen
สัณฑ์ ม่วงน้อยเจริญ
Mahidol University. Faculty of Tropical Medicine. Department of Clinical Tropical Medicine.
Wattana Leowattana
Keywords: Chronic hepatitis B;Predictors;Treatment outcome;Open Access article
Issue Date: 15-Jul-2013
Citation: Aung MN, Leowattana W, Win KN, Tangpukdee N, Muangnoicharoen S. Chronic hepatitis B prognostic markers other than pre-treatment viral load predicted composite treatment outcome. J Infect Dev Ctries. 2013 Jul 15;7(7):541-9.
Abstract: INTRODUCTION: Chronic hepatitis B (CHB) is a globally common infectious disease. Its clinical course is complicated. In Southeast Asia, nucleos(t)ide analogues (NA) are commonly used drugs for CHB treatment. Composite treatment outcome has often been used in CHB clinical practice, but rarely predicted epidemiologically. This study aimed to compare the composite treatment outcome between CHB patients with low and high treatment-naïve viral load, and to identify its predictors METHODOLOGY: This retrospective cohort study followed up 95 CHB patients on NA treatment for a year. Composite treatment outcome was defined as undetectable HBV DNA level, ALT normalization and, HBeAg clearance in the case of HBeAg-positive patients. Multinomial logistic regression analysis was applied to analyze the significant treatment response predictors. RESULTS: Complete composite treatment outcome was achieved by 52% of CHB patients with an initial viral load < 6.5 log 10 copies /ml, but 31% of those had an initial viral load ≥ log 6.5 log 10 copies /ml. Outcome was predicted by HBeAg negativity (adjusted relative risk ratio, aRRR = 11.1, 95 % confidence interval, CI 3-41.3) and ALT normalization within the sixth month of therapy (aRRR = 6.7, CI 1.8-24.9). An elevation of ALT to more than 1.5 times the normal value (40 IU/ml) can lead to an incomplete response on NA therapy (aRRR = 6.2, CI 1.5-26.6.) CONCLUSION: Routine clinical markers other than pre-treatment viral load predicted composite CHB outcome on NA Therapy.
metadata.dc.identifier.url: file:///C:/Users/pat/Downloads/2759-22392-2-PB.pdf
ISSN: 1972-2680 (electronic)
2036-6590 (printed)
Appears in Collections:TM-Article

Files in This Item:
File Description SizeFormat 
tm-ar-wattana-2013.pdf715.36 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.